Brokerages Set Theravance Biopharma Inc (TBPH) Price Target at $40.60

Theravance Biopharma Inc (NASDAQ:TBPH) has earned an average recommendation of “Hold” from the eight analysts that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $40.60.

Several research analysts recently commented on the stock. ValuEngine upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a report on Thursday, August 9th. Piper Jaffray Companies restated an “overweight” rating and issued a $55.00 price target on shares of Theravance Biopharma in a report on Wednesday, August 1st. Cantor Fitzgerald set a $55.00 price target on shares of Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, August 1st. Needham & Company LLC restated a “buy” rating and issued a $40.00 price target on shares of Theravance Biopharma in a report on Wednesday, August 1st. Finally, BidaskClub upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd.

In other Theravance Biopharma news, SVP Philip D. Worboys sold 6,393 shares of the stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $28.50, for a total value of $182,200.50. Following the completion of the sale, the senior vice president now owns 166,753 shares of the company’s stock, valued at $4,752,460.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Bradford J. Shafer sold 31,300 shares of the stock in a transaction that occurred on Wednesday, August 8th. The shares were sold at an average price of $27.94, for a total transaction of $874,522.00. Following the completion of the sale, the executive vice president now directly owns 127,606 shares of the company’s stock, valued at approximately $3,565,311.64. The disclosure for this sale can be found here. Insiders sold 88,555 shares of company stock valued at $2,425,865 in the last ninety days. 6.10% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of TBPH. SG Americas Securities LLC acquired a new stake in shares of Theravance Biopharma during the first quarter worth approximately $130,000. Swiss National Bank grew its position in shares of Theravance Biopharma by 5.3% during the first quarter. Swiss National Bank now owns 75,142 shares of the biopharmaceutical company’s stock worth $1,822,000 after buying an additional 3,800 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of Theravance Biopharma by 4.7% during the first quarter. Schwab Charles Investment Management Inc. now owns 209,075 shares of the biopharmaceutical company’s stock worth $5,071,000 after buying an additional 9,398 shares in the last quarter. Northern Trust Corp grew its position in shares of Theravance Biopharma by 0.9% during the first quarter. Northern Trust Corp now owns 516,551 shares of the biopharmaceutical company’s stock worth $12,526,000 after buying an additional 4,509 shares in the last quarter. Finally, Woodford Investment Management Ltd grew its position in shares of Theravance Biopharma by 1.4% during the first quarter. Woodford Investment Management Ltd now owns 10,898,879 shares of the biopharmaceutical company’s stock worth $264,297,000 after buying an additional 151,771 shares in the last quarter. 85.80% of the stock is owned by institutional investors.

NASDAQ TBPH traded up $0.98 during mid-day trading on Friday, hitting $31.17. The company’s stock had a trading volume of 341,400 shares, compared to its average volume of 228,896. Theravance Biopharma has a 52-week low of $21.27 and a 52-week high of $35.90. The company has a debt-to-equity ratio of 6.52, a quick ratio of 3.95 and a current ratio of 4.14. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of -5.77 and a beta of 1.90.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.20) by $0.44. Theravance Biopharma had a negative net margin of 640.07% and a negative return on equity of 261.70%. The firm had revenue of $23.48 million for the quarter, compared to analyst estimates of $9.97 million. sell-side analysts forecast that Theravance Biopharma will post -4.41 EPS for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Featured Story: What are the Different Types of Leveraged Buyouts?

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply